Abstract
The identification of new antibacterial targets is urgently needed to address multidrug resistant and latent tuberculosis infection. Sulfur metabolic pathways are essential for survival and the expression of virulence in many pathogenic bacteria, including Mycobacterium tuberculosis. In addition, microbial sulfur metabolic pathways are largely absent in humans and therefore, represent unique targets for therapeutic intervention. In this review, we summarize our current understanding of the enzymes associated with the production of sulfated and reduced sulfur-containing metabolites in Mycobacteria. Small molecule inhibitors of these catalysts represent valuable chemical tools that can be used to investigate the role of sulfur metabolism throughout the Mycobacterial lifecycle and may also represent new leads for drug development. In this light, we also summarize recent progress in the development of inhibitors of sulfur metabolism enzymes.
Keywords: Tuberculosis, mycobacteria, sulfur metabolism, enzymes, thiols, sulfation, drug design, inhibitors
Infectious Disorders - Drug Targets
Title: Drug Targets in Mycobacterial Sulfur Metabolism
Volume: 7 Issue: 2
Author(s): Devayani P. Bhave, Wilson B. Muse III and Kate S. Carroll
Affiliation:
Keywords: Tuberculosis, mycobacteria, sulfur metabolism, enzymes, thiols, sulfation, drug design, inhibitors
Abstract: The identification of new antibacterial targets is urgently needed to address multidrug resistant and latent tuberculosis infection. Sulfur metabolic pathways are essential for survival and the expression of virulence in many pathogenic bacteria, including Mycobacterium tuberculosis. In addition, microbial sulfur metabolic pathways are largely absent in humans and therefore, represent unique targets for therapeutic intervention. In this review, we summarize our current understanding of the enzymes associated with the production of sulfated and reduced sulfur-containing metabolites in Mycobacteria. Small molecule inhibitors of these catalysts represent valuable chemical tools that can be used to investigate the role of sulfur metabolism throughout the Mycobacterial lifecycle and may also represent new leads for drug development. In this light, we also summarize recent progress in the development of inhibitors of sulfur metabolism enzymes.
Export Options
About this article
Cite this article as:
Devayani P. Bhave , Wilson B. Muse III and Kate S. Carroll , Drug Targets in Mycobacterial Sulfur Metabolism, Infectious Disorders - Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/187152607781001772
DOI https://dx.doi.org/10.2174/187152607781001772 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Research Strategies of Benzimidazole Derivatives: A Review
Mini-Reviews in Medicinal Chemistry Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Recent Patents on Anti-Cancer Drug Discovery Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Synthesis of 2,4,6-Trichlorophenyl Hydrazones and their Inhibitory Potential Against Glycation of Protein
Medicinal Chemistry Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Programs to Facilitate Tuberculosis Drug Discovery: The Tuberculosis Antimicrobial Acquisition and Coordinating Facility
Infectious Disorders - Drug Targets Drugs that Inhibit Mycolic Acid Biosynthesis in Mycobacterium tuberculosis
Current Pharmaceutical Biotechnology Fluoroquinolones: Blessings Or Curses
Current Drug Targets Spices Chemoconstituents as Persuasive Inhibitor of S. typhimurium Virulent Protein L-asparaginase
Letters in Drug Design & Discovery Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Efalizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Human Immunodeficiency Virus-Mononuclear Phagocyte Interactions:Emerging Avenues of Biomarker Discovery, Modes of Viral Persistence and Disease Pathogenesis
Current HIV Research An Approach for the Rational Design of New Antituberculosis Agents
Current Drug Targets Adherence to Antiretroviral Therapy and Tuberculosis Treatment in a Prison of Tehran, Iran
Infectious Disorders - Drug Targets Prospective Observation for Seven-Year's Highly Active Antiretroviral Therapy in Chinese HIV-1 Infected Patients
Current HIV Research Molecular Dynamics Assisted Mechanistic Insight of Val430-Ala Mutation of Rv1592c Protein in Isoniazid Resistant <i>Mycobacterium Tuberculosis</i>
Current Computer-Aided Drug Design HIV Compartmentalization: A Review on a Clinically Important Phenomenon
Current HIV Research Syntheses of Ethyl Pyruvate’s Bioisosteres Inhibiting Inducible Nitric Oxide Production in Lipopolysaccharide-induced BV2 Cells
Letters in Drug Design & Discovery Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Drug Delivery Systems with Modified Release for Systemic and Biophase Bioavailability
Current Clinical Pharmacology